These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 35582449)

  • 1. RET kinase alterations in targeted cancer therapy.
    Liu X; Hu X; Shen T; Li Q; Mooers BHM; Wu J
    Cancer Drug Resist; 2020; 3(3):472-481. PubMed ID: 35582449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress and challenges in RET-targeted cancer therapy.
    Hu X; Khatri U; Shen T; Wu J
    Front Med; 2023 Apr; 17(2):207-219. PubMed ID: 37131086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.
    Subbiah V; Shen T; Terzyan SS; Liu X; Hu X; Patel KP; Hu M; Cabanillas M; Behrang A; Meric-Bernstam F; Vo PTT; Mooers BHM; Wu J
    Ann Oncol; 2021 Feb; 32(2):261-268. PubMed ID: 33161056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors.
    Khatri U; Dayal N; Hu X; Larocque E; Naganna N; Shen T; Liu X; Holtsberg FW; Aman MJ; Sintim HO; Wu J
    Mol Cancer Ther; 2023 Jun; 22(6):717-725. PubMed ID: 37070927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.
    Lin JJ; Liu SV; McCoach CE; Zhu VW; Tan AC; Yoda S; Peterson J; Do A; Prutisto-Chang K; Dagogo-Jack I; Sequist LV; Wirth LJ; Lennerz JK; Hata AN; Mino-Kenudson M; Nardi V; Ou SI; Tan DS; Gainor JF
    Ann Oncol; 2020 Dec; 31(12):1725-1733. PubMed ID: 33007380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
    Solomon BJ; Tan L; Lin JJ; Wong SQ; Hollizeck S; Ebata K; Tuch BB; Yoda S; Gainor JF; Sequist LV; Oxnard GR; Gautschi O; Drilon A; Subbiah V; Khoo C; Zhu EY; Nguyen M; Henry D; Condroski KR; Kolakowski GR; Gomez E; Ballard J; Metcalf AT; Blake JF; Dawson SJ; Blosser W; Stancato LF; Brandhuber BJ; Andrews S; Robinson BG; Rothenberg SM
    J Thorac Oncol; 2020 Apr; 15(4):541-549. PubMed ID: 31988000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives.
    Fancelli S; Caliman E; Mazzoni F; Brugia M; Castiglione F; Voltolini L; Pillozzi S; Antonuzzo L
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33806299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Precision oncology with selective RET inhibitor selpercatinib in
    Gouda MA; Subbiah V
    Ther Adv Med Oncol; 2023; 15():17588359231177015. PubMed ID: 37360768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Precision therapy for RET-altered cancers with RET inhibitors.
    Thein KZ; Velcheti V; Mooers BHM; Wu J; Subbiah V
    Trends Cancer; 2021 Dec; 7(12):1074-1088. PubMed ID: 34391699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic strategies in RET gene rearranged non-small cell lung cancer.
    Drusbosky LM; Rodriguez E; Dawar R; Ikpeazu CV
    J Hematol Oncol; 2021 Mar; 14(1):50. PubMed ID: 33771190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib.
    Shen T; Hu X; Liu X; Subbiah V; Mooers BHM; Wu J
    NPJ Precis Oncol; 2021 Jun; 5(1):48. PubMed ID: 34099825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An updated patent review of rearranged during transfection (RET) kinase inhibitors (2016-present).
    Acharya B; Frett B
    Expert Opin Ther Pat; 2022 Oct; 32(10):1067-1077. PubMed ID: 36198171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of 7-(1-methyl-1H-pyrazol-4-yl)-1,6-naphthyridine derivatives as potent inhibitors of rearranged during transfection (RET) and RET solvent-front mutants for overcoming selpercatinib resistance.
    Wu J; Mo H; An Z; Tang Z; Deng X; Zhou H; Gong Y; Zheng C; Zhuo L; Tan S
    Eur J Med Chem; 2024 Dec; 279():116891. PubMed ID: 39316846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue.
    Takamori S; Matsubara T; Haratake N; Toyokawa G; Fujishita T; Toyozawa R; Ito K; Yamaguchi M; Taguchi K; Okamoto T; Seto T
    Front Oncol; 2021; 11():704084. PubMed ID: 34497761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RET fusions in solid tumors.
    Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
    Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Desilets A; Repetto M; Yang SR; Sherman EJ; Drilon A
    Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627175
    [No Abstract]   [Full Text] [Related]  

  • 17. RET kinase inhibitors for
    Vodopivec DM; Hu MI
    Ther Adv Med Oncol; 2022; 14():17588359221101691. PubMed ID: 35756966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hallmarks of RET and Co-occuring Genomic Alterations in
    Adashek JJ; Desai AP; Andreev-Drakhlin AY; Roszik J; Cote GJ; Subbiah V
    Mol Cancer Ther; 2021 Oct; 20(10):1769-1776. PubMed ID: 34493590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective RET Inhibitors (SRIs) in Cancer: A Journey from Multi-Kinase Inhibitors to the Next Generation of SRIs.
    Clark L; Fisher G; Brook S; Patel S; Arkenau HT
    Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decade in review: a new era for RET-rearranged lung cancers.
    Choudhury NJ; Drilon A
    Transl Lung Cancer Res; 2020 Dec; 9(6):2571-2580. PubMed ID: 33489819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.